The timing aligns well—Trump's announcement came this morning and CVS dropped sharply despite positive analyst sentiment from Cantor Fitzgerald and Bernstein, who raised price targets citing turnaround progress. The underperformance versus the healthcare sector (-2.66% relative) suggests this is company-specific rather than broad healthcare weakness, consistent with CVS's significant PBM exposure. A separate RICO lawsuit filed yesterday also names CVS's PBM in an insulin pricing scheme, adding to regulatory overhang.
This is a permanent link to this specific analysis (ID: 2472)
Back to Dashboard